187 related articles for article (PubMed ID: 14988935)
1. Valsartan, captopril, or both in myocardial infarction.
Moshenyat R; Kupfer Y; Tessler S
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
[No Abstract] [Full Text] [Related]
2. Valsartan, captopril, or both in myocardial infarction.
Jorde UP
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
[No Abstract] [Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
5. Valsartan, captopril, or both in myocardial infarction.
McAnulty JH
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
[No Abstract] [Full Text] [Related]
6. [AT(1) blocker for post-infarct therapy. VALIANT Study].
Hasenfuss G
Internist (Berl); 2004 Aug; 45(8):946-8. PubMed ID: 15252713
[No Abstract] [Full Text] [Related]
7. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
8. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
[No Abstract] [Full Text] [Related]
9. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
10. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
11. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Maggioni AP; Fabbri G
Expert Opin Pharmacother; 2005 Mar; 6(3):507-12. PubMed ID: 15794740
[TBL] [Abstract][Full Text] [Related]
12. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
13. VALIANT trial results support use of valsartan in acute myocardial infarction.
Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
[No Abstract] [Full Text] [Related]
14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
15. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
Sarzani R; Dessì-Fulgheri P
J Hypertens; 2006 Aug; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
[No Abstract] [Full Text] [Related]
18. Are treatment effects of ACEI and ARB in post-MI patients homogeneous?
Miura T; Yuda S
Circ J; 2009 May; 73(5):820-1. PubMed ID: 19390158
[No Abstract] [Full Text] [Related]
19. [New options against undertreatment].
Pfeffer M
MMW Fortschr Med; 2003 Dec; 145(49):18. PubMed ID: 14963987
[No Abstract] [Full Text] [Related]
20. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
MMW Fortschr Med; 2006 Feb; 148(5):48-9. PubMed ID: 16518941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
